Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Editor's Note: LOX-Mediated Collagen Cross-linking Is Responsible for Fibrosis-Enhanced Metastasis.

Cox TR, Bird D, Baker AM, Barker HE, Ho MW, Lang G, Erler JT.

Cancer Res. 2019 Oct 1;79(19):5124. doi: 10.1158/0008-5472.CAN-19-2419. No abstract available.

PMID:
31575632
2.

Correction: LOXL2-Mediated Matrix Remodeling in Metastasis and Mammary Gland Involution.

Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, Evans HR, Gartland A, Erler JT.

Cancer Res. 2019 Oct 1;79(19):5123. doi: 10.1158/0008-5472.CAN-19-2420. No abstract available.

PMID:
31575631
3.

Preclinical rare cancer research to inform clinical trial design.

Barker HE, Scott CL.

Nat Rev Cancer. 2019 Sep;19(9):481-482. doi: 10.1038/s41568-019-0172-2. No abstract available.

PMID:
31263218
4.

Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status.

Hafsi H, Dillon MT, Barker HE, Kyula JN, Schick U, Paget JT, Smith HG, Pedersen M, McLaughlin M, Harrington KJ.

Front Oncol. 2018 Jul 13;8:245. doi: 10.3389/fonc.2018.00245. eCollection 2018.

5.

HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.

McLaughlin M, Barker HE, Khan AA, Pedersen M, Dillon M, Mansfield DC, Patel R, Kyula JN, Bhide SA, Newbold KL, Nutting CM, Harrington KJ.

BMC Cancer. 2017 Jan 31;17(1):86. doi: 10.1186/s12885-017-3084-0.

6.

An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.

Patel R, Barker HE, Kyula J, McLaughlin M, Dillon MT, Schick U, Hafsi H, Thompson A, Khoo V, Harrington K, Zaidi S.

Radiother Oncol. 2017 Mar;122(3):470-475. doi: 10.1016/j.radonc.2016.12.026. Epub 2017 Jan 25.

7.

Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.

Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhide SA, Newbold KL, Nutting CM, McLaughlin M, Harrington KJ.

Mol Cancer Ther. 2017 Jan;16(1):25-34. doi: 10.1158/1535-7163.MCT-16-0239. Epub 2016 Nov 9.

8.

CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.

Barker HE, Patel R, McLaughlin M, Schick U, Zaidi S, Nutting CM, Newbold KL, Bhide S, Harrington KJ.

Mol Cancer Ther. 2016 Sep;15(9):2042-54. doi: 10.1158/1535-7163.MCT-15-0998. Epub 2016 Jul 15.

9.

The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence.

Barker HE, Paget JT, Khan AA, Harrington KJ.

Nat Rev Cancer. 2015 Jul;15(7):409-25. doi: 10.1038/nrc3958. Review. Erratum in: Nat Rev Cancer. 2015 Aug;15(8):509.

10.

Identification of hypoxia-regulated proteins using MALDI-mass spectrometry imaging combined with quantitative proteomics.

Djidja MC, Chang J, Hadjiprocopis A, Schmich F, Sinclair J, Mršnik M, Schoof EM, Barker HE, Linding R, Jørgensen C, Erler JT.

J Proteome Res. 2014 May 2;13(5):2297-313. doi: 10.1021/pr401056c. Epub 2014 Apr 24.

PMID:
24702160
11.

Tumor-secreted LOXL2 activates fibroblasts through FAK signaling.

Barker HE, Bird D, Lang G, Erler JT.

Mol Cancer Res. 2013 Nov;11(11):1425-36. doi: 10.1158/1541-7786.MCR-13-0033-T. Epub 2013 Sep 5. Erratum in: Mol Cancer Res. 2019 Oct;17(10):2141.

12.

LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.

Chang J, Nicolau MM, Cox TR, Wetterskog D, Martens JW, Barker HE, Erler JT.

Breast Cancer Res. 2013;15(4):R67.

13.

Structural basis of the interaction of the breast cancer oncogene LMO4 with the tumour suppressor CtIP/RBBP8.

Stokes PH, Liew CW, Kwan AH, Foo P, Barker HE, Djamirze A, O'Reilly V, Visvader JE, Mackay JP, Matthews JM.

J Mol Biol. 2013 Apr 12;425(7):1101-10. doi: 10.1016/j.jmb.2013.01.017. Epub 2013 Jan 23.

PMID:
23353824
14.

LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis.

Cox TR, Bird D, Baker AM, Barker HE, Ho MW, Lang G, Erler JT.

Cancer Res. 2013 Mar 15;73(6):1721-32. doi: 10.1158/0008-5472.CAN-12-2233. Epub 2013 Jan 23.

15.

The rationale for targeting the LOX family in cancer.

Barker HE, Cox TR, Erler JT.

Nat Rev Cancer. 2012 Jul 19;12(8):540-52. doi: 10.1038/nrc3319. Review.

PMID:
22810810
16.

The potential for LOXL2 as a target for future cancer treatment.

Barker HE, Erler JT.

Future Oncol. 2011 Jun;7(6):707-10. doi: 10.2217/fon.11.46. No abstract available.

PMID:
21675833
17.

LOXL2-mediated matrix remodeling in metastasis and mammary gland involution.

Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, Evans HR, Gartland A, Erler JT.

Cancer Res. 2011 Mar 1;71(5):1561-72. doi: 10.1158/0008-5472.CAN-10-2868. Epub 2011 Jan 13. Erratum in: Cancer Res. 2019 Oct 1;79(19):5123.

18.

Deaf-1 regulates epithelial cell proliferation and side-branching in the mammary gland.

Barker HE, Smyth GK, Wettenhall J, Ward TA, Bath ML, Lindeman GJ, Visvader JE.

BMC Dev Biol. 2008 Oct 1;8:94. doi: 10.1186/1471-213X-8-94.

19.

The effect of agar on the bacteriostatic activities of acridine.

BARKER HE.

Australas J Pharm. 1949 May 30;30(353):573. No abstract available.

PMID:
18152915

Supplemental Content

Loading ...
Support Center